Is There a Role for Intraperitoneal Therapy in the Management of Gastrointestinal Malignancies?

References

• Markman M. Intraperitoneal chemotherapy for malignant diseases of the gastrointestinal tract. Surg Gynecol Obstet 1987; 164: 239–93
   Google Scholar
• Markman M. Intraperitoneal chemotherapy. Semin Oncol 1991; 18: 248–254
   PubMed Web of Science ®Google Scholar
• Dedrick R L, Myers C E, Bungay P M. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62: 1–9
   PubMedGoogle Scholar
• Collins J M. Pharmacokinetic rationale for regional drug delivery. J Clin Oncol 1984; 2: 498–504
   PubMed Web of Science ®Google Scholar
• Los G, Mutsaers P HA, Van der Vijgh W JF. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy. Cancer Res 1989; 49: 3380–3384
   PubMed Web of Science ®Google Scholar
• Nederman T, Carlsson J. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother Pharmacol 1984; 13: 131–135
   PubMed Web of Science ®Google Scholar
• Ozols R F, Locker G Y, Doroshow J H. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 1979; 39: 3209–3214
   PubMed Web of Science ®Google Scholar
• Los G, Verdegaal E ME, Mutsaers P HA. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 1991; 28: 159–165
   PubMed Web of Science ®Google Scholar
• Markman M, Reichman B, Hakes T. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin. J Clin Oncol 1991; 9: 1801–1805
   PubMed Web of Science ®Google Scholar
• Muggia F M, Groshen S, Russell C. Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: Analysis of results by prior sensitivity to platinum-based regimens. Gynecol Oncol 1993; 50: 232–238
   PubMed Web of Science ®Google Scholar
• Markman M, Berek J S, Blessing J A. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based IP chemotherapy: Lessons learned from a Gynecologic Oncology Group phase II trial of IP cisplatin and recombinant alpha-interferon. Gynecol Oncol 1992; 453–8
   Google Scholar
• Ozols R F, Grotzinger K R, Fisher R I. Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer. Cancer Res 1979; 39: 3202–3208
   PubMed Web of Science ®Google Scholar
• Andrews P A, Velury S, Mann S C, Howell S B. Cis-diam-minedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 1988; 48: 68–73
   PubMed Web of Science ®Google Scholar
• Sugarbaker P H, Graves T, DeBruijn E A. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: Pharmacological studies. Cancer Res 1990; 50: 5790–5794
   PubMed Web of Science ®Google Scholar
• Sugarbaker P H, Zhu B W, Sese G B. Peritoneal carcinomatosis from appendiceal cancer; results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum 1993; 36: 323–329
   PubMed Web of Science ®Google Scholar
• Leichman L, Silberman C G, Leichman C P. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: A University of Southern California pilot program. J Clin Oncol 1992; 10: 1933–1942
   PubMed Web of Science ®Google Scholar
• Atiq O T, Kelsen D P, Shiu M H. Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. J Clin Oncol 1993; 11: 425–433
   PubMed Web of Science ®Google Scholar
• Reichman B, Markman M, Hakes T. Phase I trial of concurrent intraperitoneal and continuous infusion of 5-fluorouracil plus intraperitoneal cisplatin in patients with refractory cancer. Reg Cancer Ther 1989; 2: 223–228
   Google Scholar
• Hagiwara A, Takahashi T, Kojima O. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992; 339: 629–631
   PubMed Web of Science ®Google Scholar
• Conway J G, Popp J A, Thurman R G. Microcirculation of hepatic nodules from diethylnitrosamine-treated rats. Cancer Res 1985; 45: 3620–3625
   PubMed Web of Science ®Google Scholar
• Lin G, Lunderquist A, Hagerstrand I, Boijsen E. Postmortem examination of the blood supply and vascular pattern of small liver metastases in man. Surgery 1984; 96: 517–526
   PubMed Web of Science ®Google Scholar
• Speyer J L, Collins J M, Dedrick R L. Phase I pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 1980; 40: 567–572
   PubMed Web of Science ®Google Scholar
• Kraft A R, Tompkins R K, Jesseph J E. Peritoneal electrolyte absorption: analysis of portal, systemic venous and lymphatic transport. Surgery 1968; 64: 148–153
   PubMed Web of Science ®Google Scholar
• Lukas G, Brindle S, Greengard P. The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther 1971; 178: 562–566
   PubMed Web of Science ®Google Scholar
• Dedrick R L. Arterial drug infusion: Pharmacokinetic problems and pitfalls. J Natl Cancer Inst 1988; 80: 533–89
   Google Scholar
• Lutz R J, Miller D L. Mixing studies during hepatic artery infusion in an in vitro model. Cancer 1988; 62: 1066–1073
   PubMed Web of Science ®Google Scholar
• Sugarbaker P H, Cunliffe W, Belliveau J F. Rationale for perioperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy. Reg Cancer Treat 1988; 1: 66–79
   Google Scholar